Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 22;17(6):e86567.
doi: 10.7759/cureus.86567. eCollection 2025 Jun.

Double Myopic Choroidal Neovascular Membranes (CNVMs): A Case Report

Asli Perente  1 , Aikaterini Giannoukaki  1 , Doukas Dardabounis  1 , Tryfon Rotsos  1 , Georgios Labiris  1
Affiliations
Case Reports

Double Myopic Choroidal Neovascular Membranes (CNVMs): A Case Report

Asli Perente et al. Cureus. .

Abstract

Myopic choroidal neovascularization (CNV) is the most common cause of visual morbidity in patients with pathologic myopia (PM). Early diagnosis and management are crucial to prevent permanent loss of central vision. Optical coherence tomography (OCT) and OCT angiography (OCT-A) are the key diagnostic modalities for identifying and monitoring this vision-threatening complication. We report an unusual case of a female patient with two myopic CNVs in the same eye, clearly depicted using OCT-A and successfully managed with anti-vascular endothelial growth factor (anti-VEGF) injections. This rare instance warrants further study to draw more definite conclusions regarding this common complication and its response to treatment.

Keywords: anti-vegf; choroidal neovascular membrane; myopic choroidal neovascular membrane; oct angiography; pathologic myopia.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Color fundus image of the left eye (OS) showing chorioretinal atrophy and Fuchs spot (red arrow) with adjacent greyish lesion in the fovea (white arrow)
Figure 2
Figure 2. OCT of the left eye (OS) indicating two hyperreflective lesions above the RPE (red arrows) with SRF (white arrow)
OCT: optical coherence tomography, RPE: retinal pigment epithelium, SRF: subretinal fluid.
Figure 3
Figure 3. OCT-angiography of the left eye (OS) showing two separate lacy networks of neovascularization (red circles) confirming the presence of dual myopic CNVs
The bottom-left image is a horizontal OCT scan, and the bottom-right image is a vertical OCT scan. OCT: optical coherence tomography, CNV: choroidal neovascularization, LPT: lesion projection thickness, ILM: internal limiting membrane, IPL: inner plexiform layer, OPL: outer plexiform layer, BRM: Bruch’s membrane.
Figure 4
Figure 4. OCT-angiography of the left eye (OS) after two injections of ranibizumab with complete resolution of SRF and inactivation of CNVs (red circles) with RPE cover
The bottom-left image is a horizontal OCT scan, and the bottom-right image is a vertical OCT scan. OCT: optical coherence tomography, CNV: choroidal neovascularization, RPE: retinal pigment epithelium, SRF: subretinal fluid, LPT: lesion projection thickness, ILM: internal limiting membrane, IPL: inner plexiform layer, OPL: outer plexiform layer, BRM: Bruch’s membrane.
See this image and copyright information in PMC

References

    1. Myopia. Baird PN, Saw SM, Lanca C, et al. Nat Rev Dis Primers. 2020;6:99. - PubMed
    1. More than fifty percent of the world population will be myopic by 2050. Nouraeinejad A. Beyoglu Eye J. 2021;6:255–256. - PMC - PubMed
    1. IMI pathologic myopia. Ohno-Matsui K, Wu PC, Yamashiro K, et al. Invest Ophthalmol Vis Sci. 2021;62:5. - PMC - PubMed
    1. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Ophthalmology. 2004;111:62–69. - PubMed
    1. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, Jonas JB. Ophthalmology. 2006;113:1134–1111. - PubMed

Publication types